Introduction {#sec1}
============

The coronavirus disease-2019 (COVID-19) outbreak is an ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak was initially identified in Wuhan, China in December 2019 and has been a public health emergency of international concern since its spread within China and worldwide.[@bib1], [@bib2], [@bib3], [@bib4]

Many COVID-19 patients are reportedly asymptomatic or mildly ill with only flu-like symptoms such as fever and cough. However, many patients develop pneumonia, acute respiratory distress syndrome, and multiple organ failure in a short time.[@bib5], [@bib6], [@bib7] Identifying the risk factors for developing pneumonia, longer quarantine duration, and mortality in COVID-19 patients is important. However, due to the Taiwan government\'s rapid action on the disease, including border control, compulsory quarantine, and comprehensive contact tracing, Taiwan has been able to contain the pandemic. Thus, there are limited data regarding the clinical characteristics of COVID-19 patients in Taiwan.

Our hospital, the Tri-Service General Hospital, is a tertiary medical center in Northern Taiwan with 12 airborne infection isolation rooms and eight airborne infection isolation critical care rooms. Since February 4, 2020, 28 confirmed COVID-19 patients were admitted to our airborne infection isolation rooms. All patients were discharged with recovery. Due to the limited available data on the clinical characteristics of COVID-19 patients in Taiwan, we conducted this study to clarify the risk factors for developing pneumonia and longer quarantine duration in COVID-19 patients in Taiwan.

Methods {#sec2}
=======

Study population {#sec2.1}
----------------

Adult patients (age ≥20 years) with COVID-19 infection, as confirmed by positive identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral nucleic acids, were enrolled. These were confirmed using real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assays from oropharyngeal swab specimens collected between February 4, 2020, and July 6, 2020. Positive patients were admitted to our airborne infection isolation wards at Tri- Service General Hospital and included in our study. The study was approved by the Institutional Review Board of Tri Service General Hospital and informed consent was obtained from the included patients.

Demographic, clinical symptom, laboratory, and medication data {#sec2.2}
--------------------------------------------------------------

Relevant clinical data on the enrolled patients, including age, sex, height, weight, imported or indigenous transmission, underlying diseases, clinical symptoms, laboratory data, treatment medicine, and hospitalization days, were recorded. Pneumonia was diagnosed as the presence of lower respiratory tract symptoms such as cough, systemic symptoms such as fever, and new onset radiology findings of infiltration.[@bib8] ^,^ [@bib9]

Data on the clinical symptoms were collected from patient accounts at and during admission. Laboratory data including white cell counts, platelet counts, neutrophil and lymphocyte ratios; total bilirubin, albumin, creatine kinase C-reactive protein (CRP), D-dimer, procalcitonin, myoglobulin, ferritin, lactic dehydrogenase, and alkaline phosphatase levels; and erythrocyte sedimentation rates were examined in patients 24 h after admission. Renal function was assessed based on blood urea nitrogen and creatinine measurements, while liver function was assessed according to aspartate transaminase and alanine transaminase concentrations. The cycle threshold (Ct) values of the COVID-19 RT-PCR assays from the oropharyngeal swab specimens were also obtained. Patients who were discharged fulfilled the criteria decided by Taiwan\'s Centers for Disease Control, which required the symptoms to have subsided as well as three negative COVID-19 test results from oropharyngeal swab specimens and sputum.

Statistical analysis {#sec2.3}
--------------------

The patients were sub-grouped according to demographic data, symptoms, laboratory data, and treatment medicines to clarify the risk factors for developing pneumonia and long quarantine duration. All results were analyzed using a commercially available software package (IBM SPSS Statistics for Windows, version 21.0; IBM Corp., Armonk, NY, USA). Categorical variables were analyzed using chi-squared tests. Continuous variables with categorical variables were analyzed using independent sample *t*-tests. The odds ratio of each factor were obtained by logistic regression tests. All *p-*values were two-tailed, and values less than 0.05 were considered statistically significant.

Results {#sec3}
=======

Our study included a total of 28 COVID-19 confirmed patients hospitalized and discharged between February 4, 2020, and July 6, 2020 at Tri Service General Hospital. The median age of these patients was 41 years (range, 18--80 years). Among them, 17 patients (60.7%) had pneumonia. All 28 patients recovered and were discharged, with a median hospital quarantine duration was 27.2 days. The median Charlson comorbidity index of these patients was 0.93.

Associations between demographic data and outcomes {#sec3.1}
--------------------------------------------------

The sub-grouped demographic data are shown in [Table 1](#tbl1){ref-type="table"} . The incidence between men and women was equal (50% men vs. 50% women). Most of the patients (n = 25; 89.3%) had a travel history and were classified as imported cases. Four patients (14.3%) had underlying hypertension and five (17.9%) had underlying hyperlipidemia. More patients who were 40 years old or older developed pneumonia compared to patients younger than 40 (84.6% vs. 40%; *p* = 0.024). More patients who developed pneumonia had a BMI greater than or equal to 25 compared to those with a BMI under 25 kg/m^2^ (100% vs. 47.6%; *p =* 0.014). More patients shorter than 1.7 m developed pneumonia compared to patients taller than 1.7 m (25% vs. 75%; *p =* 0.023). Patients 40 years of age or older had a longer quarantine duration compared to that in patients younger than 40 years (31.7 ± 10.8 days vs. 23.3 ± 8.1 days; *p =* 0.026). Patients with a higher Charlson comorbidity index had a longer quarantine duration than that in patients with a lower Charlson comorbidity index (32.2 ± 11.6 days vs. 24 ± 8.1 days; *p =* 0.037).Table 1Demographic data of patients with coronavirus disease-2019 (COVID-19).Table 1Number (%)No pneumoniaPneumoniaOdds ratio*p* valueQuarantine duration (days)*p* valueSexMale14 (50%)7 (50%)7 (50%)0.4 (0.084--1.909)28.9 ± 7.7Female14 (50%)4 (28.6%)10 (71.4%)10.2525.5 ± 12.40.387Age (years)≥4013 (46.4%)2 (15.4%)11 (84.6%)8.25 (1.328--51.263)31.7 ± 10.8\<4015 (53.6%)9 (60%)6 (40%)10.02423.3 ± 8.10.026BMI (kg/m^2^)≥257 (25)07 (100%)NA34.0 ± 11.7\<2521 (75%)11 (52.4%)10 (47.6%)NA0.01425.0 ± 8.90.051Height (m)≥1.78 (28.6%)6 (75%)2 (25%)0.111 (0.017--0.738)29.1 ± 8.1\<1.720 (71.4%)5 (20%)15 (75%)10.02326.5 ± 11.10.544SourceImported25 (89.3%)9 (36%)16 (64%)3.6 (0.282--44.884)27.2 ± 10.6Indigenous3 (10.7%)2 (66.7%)1 (33.3%)10.32727.6 ± 9.20.937Charlson Index≥111 (39.3%)2 (18.1%)9 (81.8%)5.1 (0.833--30.75)32.2 ± 11.6\<117 (60.7%)9 (52.9%)8 (47.1%)10.07824 ± 8.10.037

Associations between clinical symptoms and outcomes {#sec3.2}
---------------------------------------------------

The symptoms of the included COVID-19 patients are listed in [Table 2](#tbl2){ref-type="table"} . The most frequent symptoms were cough (n = 23, 82.1%) and fever (n = 17, 63%). Seven patients (25%) had a distorted sense of taste and 10 patients (35.7%) had a distorted sense of smell. Ten patients (35.7%) had shortness of breath. Other symptoms included headache (14.3%), myalgia (17.9%), rhinorrhea (42.9%), sore throat (28.6%), diarrhea (35.7%), chest pain (17.9%), chills (17.9%), nausea and vomiting (10.7%), and eye illness (3.6%). Patients with fever seemed more prone to develop pneumonia than patients without (82.4% vs. 27.3%; *p =* 0.007). Patients with shortness of breath or chills also had a higher possibility of having pneumonia than did patients without (shortness of breath vs. no shortness of breath; 90% vs. 44.4%; *p =* 0.036) (chills vs. no chills; 100% vs. 52.2%; *p =* 0.047).Table 2Symptoms of patients with coronavirus disease-2019 (COVID-19).Table 2Number (%)No pneumoniaPneumoniaOdds ratio*p* valueQuarantine duration (days)*p* valueFeverYes17 (60.7%)3 (17.6%)14 (82.4%)12.444 (2.015--76.872)29.7 ± 9.4No11 (39.3%)8 (72.7%)3 (27.3%)10.00723.4 ± 10.70.198CoughYes23 (82.1%)9 (39.1%)14 (60.9%)1.037 (0.144--7.477)27.3 ± 10.2No5 (17.9%)2 (40%)3 (60%)10.97127 ± 11.90.96HeadacheYes4 (14.3%)04 (100%)NA22.7 ± 3.7No24 (85.7%)11 (45.8%)13 (54.2%)NA0.08227.9 ± 10.80.357MyalgiaYes5 (17.9%)1 (20%)4 (80%)3.077 (0.296--31.982)32 ± 9.5No23 (82.1%)10 (43.5%)13 (56.5%)10.34726.2 ± 10.30.258Distorted sense of tasteYes7 (25%)3 (42.9%)4 (57.1%)0.821 (0.144--4.66)29.6 ± 8.3No21 (75%)8 (38.1%)13 (61.9%)10.82326.4 ± 10.90.493Distorted sense of smellYes10 (35.7%)5 (50%)5 (50%)0.5 (0.103--2.428)25.7 ± 10.1No18 (64.3%)6 (33.3%)12 (66.7%)10.3928.1 ± 10.50.571RhinorrheaYes12 (42.9%)4 (33.3%)8 (66.7%)1.556 (0.329--7.361)26.8 ± 10No16 (57.1%)7 (43.8%)9 (56.2%)10.57727.6 ± 10.70.84Sore throatYes8 (28.6%)1 (12.5%)7 (87.5%)7 (0.722--67.84)28.6 ± 9.9No20 (71.4%)10 (50%)10 (50%)10.09326.7 ± 10.60.654DiarrheaYes10 (35.7%)2 (20%)8 (80%)4 (0.659--24.297)25.3 ± 11.4No18 (64.3%)9 (50%)9 (50%)10.13228.3 ± 9.80.473Chest painYes5 (17.9%)1 (20%)4 (80%)3.077 (0.296--31.982)21.6 ± 4.2No23 (82.1%)10 (43.5%)13 (56.5%)10.34728.4 ± 10.80.182Shortness of breathYes10 (35.7%)1 (10%)9 (90%)11.25 (1.167--108.407)30.1 ± 11.8No18 (64.3%)10 (55.6%)8 (44.4%)10.03625.6 ± 9.30.276ChillnessYes5 (17.9%)05 (100%)NA20.8 ± 4No23 (82.1%)11 (47.8%)12 (52.2%)NA0.04728.6 ± 10.70.125Nausea/vomitingYes3 (10.7%)05 (100%)NA19 ± 2.6No25 (89.3%)11 (44%)14 (56%)NA0.1428.2 ± 10.40.146Eye illnessYes1 (3.6%)01 (100%)NA23No27 (96.4%)11 (40.7%)16 (59.3%)NA0.41327.4 ± 10.40.684

Associations between laboratory findings and outcomes {#sec3.3}
-----------------------------------------------------

The laboratory results of these COVID-19 patients, confirmed within 24 h after admission, are listed in [Table 3](#tbl3){ref-type="table"} . Among these confirmed cases, 16 patients (57.1%) had a relatively lower absolute lymphocyte count (ALC) (\<1500/uL). They were more prone to a longer quarantine duration than that in patients with a higher ALC (21.9 ± 9 days vs. 31.2 ± 9.5 days; *p =* 0.028). Eight patients (28.6%) had a relatively lower platelet count (\<200,000/uL). They were more prone to having pneumonia (45% vs. 100%; *p =* 0.007) and a longer quarantine duration (24.4 ± 8.6 days vs. 34.3 ± 11 days; *p =* 0.016) than those in patients with a higher platelet count. Patients with relatively low serum sodium (\<140 mmol/L) (71.4%) levels or higher CRP levels (≥1 mg/dL) were prone to longer quarantine durations than patients with higher serum albumin or lower CRP levels (Na ≥140 mmol/L vs. Na \< 140 mmol/L; 19.1 ± 5.6 days vs. 30.5 ± 10 days; *p =* 0.006) (CRP ≥1 mg/dl vs. CRP \<1 mg/dl; 32.5 ± 11.8 days vs 24.3 ± 8.2 days; *p =* 0.04)Table 3Laboratory findings of patients with coronavirus disease-2019 (COVID-19) during admission.Table 3Number (%)No pneumoniaPneumoniaOdds ratio*p* valueQuarantine duration (day)*p* valueWhite blood cell count (/uL)≥400023 (82.1%)10 (43.5%)13 (56.5%)127.7 ± 10.7\<40005 (17.9%)1 (20%)4 (80%)2.571 (0.246--26.851)0.4324.8 ± 8.80.572Absolute lymphocyte count (/uL)≥150012 (42.9%)7 (58.3%)5 (41.7%)121.9 ± 9.0\<150016 (57.1%)4 (25%)12 (75%)4.2 (0.838--21.047)0.08131.2 ± 9.50.028Platelets (/uL)≥200,00020 (71.4%)11 (55%)9 (45%)NA24.4 ± 8.6\<200,0008 (28.6%)08 (100%)NA0.00734.4 ± 11.00.016CK (u/L)≥5011 (44%)4 (36.4%)7 (63.6%)127.9 ± 6.5\<5014 (56%)5 (35.7%)9 (69.2%)1.029 (0.199--5.326)0.97327.4 ± 12.20.901Cr (mg/dL)\<122 (78.6%)10 (45.5%)12 (54.5%)127.9 ± 10.9≥16 (21.4%)1 (16.66%)5 (83.3%)4.167 (0.416--41.776)0.22527.1 ± 6.40.869AST (u/L)≥2013 (46.4%)6 (46.2%)7 (53.8%)126.3 ± 12.4\<2015 (53.6%)5 (33.33%)10 (66.7%)1.714 (0.371--7.918)0.4928 ± 8.40.672ALT (u/L)≥2011 (39.3%)4 (36.36%)7 (63.6%)125.7 ± 13.1\<2017 (60.7%)7 (41.2%)10 (58.8%)0.816 (0.171--3.895)0.79928.2 ± 8.30.548Total bilirubin (mg/dL)≥0.518 (66.7%)8 (44.44%)10 (55.6%)128.5 ± 11.3\<0.59 (33.3%)2 (22.2%)7 (77.8%)2.8 (0.451--17.383)0.26924.8 ± 8.30.387Albumin (g/dL)≥414 (53.8%)4 (28.6%)10 (71.4%)126.7.1 ± 9.0\<412 (46.2%)5 (41.6%)7 (58.3%)0.875 (0.171--4.472)0.87329.3 ± 7.60.597Na (mmol/L)≥1408 (28.6%)4 (50%)4 (50%)119.1 ± 5.6\<14020 (71.4%)7 (35%)13 (65%)1.857 (0.352--9.795)0.46630.5 ± 10.00.006K (mmol/LL)≥3.523 (82.1%)10 (43.5%)13 (56.5%)127.0 ± 8.0\<3.55 (17.9%)1 (20%)4 (80%)3.077 (0.296--31.982)0.34728.2 ± 18.90.818C-reactive protein (mg/dLL)≥110 (35.7%)2 (20%)8 (80%)132.5 ± 11.8\<118 (64.3%)9 (50%)9 (50%)0.281 (0.046--1.734)0.13224.3 ± 8.20.04D-dimer (μg/mL)≥0.53 (27.3%)1 (33.33%)2 (66.7%)132 ± 7\<0.58 (72.7%)2 (25%)6 (75%)1.5 (0.084--26.855)0.78224.1 ± 12.90.354Procalcitonin (ng/mL)≥0.037 (70%)1 (14.28%)6 (85.7%)NA31.2 ± 12.2\<0.033 (30%)03 (100%)NA0.49033.3 ± 9.80.806Myoglobulin (ng/mL)≥108 (66.7%)3 (37.5%)5 (62.5%)125.7 ± 7.8\<104 (33.3%)1 (25%)3 (75%)1.8 (0.124--26.196)0.66525.7 ± 9.01Ferrtin (ng/mL)≥2009 (56.2%)2 (18.18%)7 (81.8%)128.2 ± 10.6\<2007 (43.8%)4 (57.1%)3 (42.9%)0.167 (0.02--1.419)0.10125.6 ± 10.10.599Lactate dehydrogenase (u/L)≥15015 (57.7%)5 (33.3%)10 (66.7%)126.5 ± 11.4\<15011 (42.3%)5 (45.45%)6 (54.5%)0.6 (0.121--2.973)0.53228.4 ± 7.40.619Alkaline-phosphatase (u/L)≥5015 (62.5%)6 (40%)9 (60%)131.2 ± 9.6\<509 (37.5%)2 (22.2%)7 (77.8%)2.333 (0.356--15.3)0.37725 ± 9.90.147Erythrocyte sedimentation rate (mm/hr)≥206 (75%)1 (16.66%)5 (83.3%)NA24.6 ± 6.9\<202 (25%)02 (100%)NA0.53731.5 ± 12.00.337Cycle threshold of RT-PCR≥2516 (59.3%)6 (37.5%)10 (62.5%)129.0 ± 8.7\<2511 (40.7%)4 (36.36%)7 (63.6%)1.05 (0.214--5.158)0.95225.9 ± 11.80.432

Associations between drug choices and outcomes {#sec3.4}
----------------------------------------------

The medications prescribed to these confirmed COVID-19 patients are listed in [Table 4](#tbl4){ref-type="table"} . Hydroxychloroquine was administered to 22 (78.6%) of the 28 patients. The combined use of hydroxychloroquine and azithromycin was prescribed to 13 patients (46.4%). The combined use of hydroxychloroquine, azithromycin, ceftriaxone, and teicoplanin was prescribed to three patients (10.7%). Three patients (10.7%) did not receive any antibiotics or hydroxychloroquine. The quarantine durations did not differ significantly between patients treated with different medicine combinations ([Table 4](#tbl4){ref-type="table"}).Table 4Treatment medications and durations of coronavirus disease-2019 (COVID-19) patient quarantine.Table 4Medication CombinationsNumber (%)Quarantine duration (days)*p* valueHydroxychloroquine+Azithromycin+Ceftriaxone+TeicoplaninYes3 (10.7%)28.6 ± 2.8No25 (89.3%)27.0 ± 10.80.801Hydroxychloroquine+Azithromycin+CeftriaxoneYes10 (35.7%)27.4 ± 9.3No18 (64.3%)26.8 ± 12.30.877Hydroxychloroquine+AzithromycinYes13 (46.4%)28.4 ± 11.3No15 (53.6%)26.1 ± 9.50.56Hydroxychloroquine+CeftriaxoneYes13 (46.4%)25.3 ± 11No15 (53.6%)28.8 ± 9.60.39HydroxychloroquineYes22 (78.6%)26.3 ± 10.7No6 (21.4%)30.6 ± 8.40.363CeftriaxoneYes16 (57.1%)27.6 ± 11.2No12 (42.9%)26.7 ± 9.30.812AzithromycinYes13 (46.4%)28.4 ± 11.3No15 (53.6%)26.1 ± 9.50.56No Antibiotics or HydroxychloroquineYes3 (10.7%)24 ± 3.6No25 (89.3%)27.6 ± 10.80.576

Discussion {#sec4}
==========

The COVID-19 outbreak first occurred in Wuhan, China in December 2019 and has spread worldwide in just 2 months. Since February 21, 451 confirmed COVID-19 cases have been reported in Taiwan. Due to the Taiwan government\'s rapid actions, the country has been able to contain the pandemic. Thus, there are limited data on the clinical characteristics of COVID-19 patients in Taiwan. Since February 2020, 28 confirmed COVID-19 patients had been admitted to our hospital. All patients recovered and were discharged. Our study aimed to present the clinical characteristics of these confirmed COVID-19 cases in Taiwan and to clarify the risk factors for developing pneumonia and longer quarantine durations.

Confirmed COVID-19 patients in Taiwan can leave quarantine only after three negative COVID-19 tests. Due to the long communicability period of COVID-19 and the relatively mild disease severity of confirmed patients in our hospital, all of our COVID-19 patients recovered from the disease before they obtained three negative COVID-19 test results required to leave quarantine. Thus, the quarantine duration in the present study more reflected the time required for virus eradication rather than disease severity.

All patients with confirmed COVID-19 in our hospital recovered eventually. Several factors may have contributed to the lack of mortality. First, our COVID-19 patients were relatively young with well performance. Most were classified as imported cases (n = 25; 89.3%) and had gone abroad for study or tourism. As in a previous study, patients with comorbidity showed poorer clinical outcomes than those without.[@bib10] Second, most of our COVID-19 patients had relatively mild illnesses. Among them, only one patient developed acute respiratory distress syndrome (ARDS) (n = 1; 3.6%) while other studies reported much higher percentages of patient developing ARDS.[@bib11] ^,^ [@bib12] Third, most of our patients were diagnosed in the early stage of disease. Symptomatic patients who visited our hospital with a travel or contact history were all referred to our emergency room and tested for COVID-19. Timely identification of patients at risk allowed early diagnosis and relatively mild disease severity in our patients. Finally, successful supportive treatment may also play a role. Optimized supportive care remains the mainstay of therapy for COVID-19, and the clinical efficacy for the subsequent agents is still under investigation.

In our study, older COVID-19 patients (age ≥40 years) were prone to having pneumonia and a longer quarantine duration compared to younger patients ([Table 1](#tbl1){ref-type="table"}). Older age is reportedly associated with higher mortality in COVID-19 patients.[@bib13] This may be due to the age-dependent differences in activity and expression of pulmonary renin-angiotensin system components under pathophysiologic conditions.[@bib14] An animal study reported increased fluid-soluble angiotensin-converting enzyme activity was in bronchoalveolar lavage of rats exposed to lipopolysaccharide. This increased enzyme activity was significantly higher in elderly rats.[@bib14] This may indicate that the elderly more prone to the development and progression of lung injuries. COVID-19 patients who were overweight (BMI ≥25 kg/m^2^) were more likely to have pneumonia than were non-overweight patients ([Table 1](#tbl1){ref-type="table"}). This risk factor was also reported in H1N1-infected patients. In previous studies, obesity was found to increase H1N1 vulnerability[@bib15] and may be associated with the need for hospitalization and death in H1N1 patients.[@bib16] Patients with a high Charlson comorbidity index (≥1) in our study had longer quarantine durations ([Table 1](#tbl1){ref-type="table"}). A previous study suggested that the Charlson comorbidity index might serve as an independent determinant for hospital mortality in COVID-19 patients.[@bib17] Our study revealed that it might also serve as a determinant for hospital quarantine durations in COVID-19 patients.

The most frequent symptoms in our patients were cough and fever ([Table 2](#tbl2){ref-type="table"}). This finding was similar to those of other studies.[@bib13] A growing number of papers have reported smell or taste disturbances in COVID-19 patients.[@bib18] In our study, 10 (35.7%) and seven patients (25%) had distorted senses of smell and taste, respectively ([Table 2](#tbl2){ref-type="table"}). Changes in smell and taste in COVID-19 patients may be related to angiotensin-converting enzyme 2 protein in nasal respiratory and olfactory epithelial cells.[@bib19] Most of the patients in our hospital with distorted smell or taste gradually recovered their senses following their recovery. Based on these symptoms, a team at King\'s College London developed a model to identify which combination of symptoms could predict COVID-19 cases, including a combination of loss of smell and taste, fever, persistent cough, fatigue, diarrhea, abdominal pain, and loss of appetite.[@bib20] They found that the strongest predictor was loss of smell and taste.[@bib20] Clinical physicians should be on alert in patients with symptoms of distorted smell or taste.

A previous study reported that lymphopenia might be associated with severe COVID-19.[@bib21] The results of our study showed that it may also be associated with longer hospital quarantine ([Table 3](#tbl3){ref-type="table"}). A meta-analysis of nine studies suggested that thrombocytopenia was significantly associated with COVID-19 severity.[@bib22] A more sizable drop in platelet counts was noted, especially in non-survivors.[@bib22] In our study, a lower platelet count (\<200,000/uL) might also be associated with developing pneumonia and longer hospital quarantine duration ([Table 3](#tbl3){ref-type="table"}). Lower serum sodium levels may indicate poor nutrition and health status. In our study, serum sodium (\<140 mmol/L) was associated with longer hospital quarantine ([Table 3](#tbl3){ref-type="table"}). A previous study reported a high prevalence of malnutrition in elderly COVID-19 patients.[@bib23] Low real-time RT-PCR cycle threshold (Ct) values of COVID-19 from oropharyngeal swabs indicated high viral loads. However, in our study, there was no relationship between Ct values and the occurrence of pneumonia or longer hospital quarantine. We could not predict the outcome or disease severity using the virus Ct. Yen et al. reported similar viral loads between asymptomatic and symptomatic patients.[@bib24] Additional studies are needed to clarify the correlation between viral loads and disease severity or COVID-19 patient outcomes.

Hydroxychloroquine and azithromycin reportedly decrease viral load in COVID-19 patients.[@bib25] We prescribed hydroxychloroquine to most of the enrolled patients; however, the hospital quarantine duration did not differ significantly between patients who received hydroxychloroquine and those who did not ([Table 4](#tbl4){ref-type="table"}). This may be due to the small number of cases in our study. Further studies on the efficacy of hydroxychloroquine or azithromycin are needed. However, a previous study reported that hydroxychloroquine may not reduce the need for intubation or mortality in COVID-19 patients.[@bib26] The combination of hydroxychloroquine and different antibiotics in our study did not reduce the duration of hospital quarantine ([Table 4](#tbl4){ref-type="table"}). Further studies are needed to clarify the efficacy of these agents.

Our study has several limitations. First, it was conducted in a single center; thus, the results may have some biases. Second, this was a retrospective cohort study and not all laboratory examinations were performed in all patients. Third, our treatment options were not chosen randomly, which may also have caused biases. Fourth, due to the small sample size of our study, multivariate logistic regression analysis was difficult to perform to assess the relationship between the outcome (developing pneumonia and increased quarantine duration) and the predictive factors. Further studies are needed to clarify the clinical characteristics and efficacy of treatment options in COVID-19 patients.

Conclusion {#sec5}
==========

In conclusion, among the patients with COVID-19 enrolled in our study, older age; higher BMI; shorter body height; symptoms of fever, chills, or short of breath; and lower platelet count may be associated with developing pneumonia, while older age, higher Charlson comorbidity index, lower lymphocyte count, lower platelet count, lower serum sodium level, and higher CRP level may be associated with a longer quarantine duration. Prescribing hydroxychloroquine alone or combined with other antibiotics may not reduce the duration of hospital quarantine.

Funding {#sec6}
=======

This work was supported by 10.13039/501100010425Tri-Service General Hospital, Taipei, Taiwan \[grant numbers TSGH-C108-135 and TSGH-C109-147\]; and the 10.13039/501100001868National Science Council, Taipei, Taiwan \[grant numbers MOST 106-2314-B016-024-MY3\].

Declaration of Competing Interest
=================================

The authors have no conflicts of interest relevant to this article.
